182 related articles for article (PubMed ID: 26530955)
1. A phase 1 study of lenvatinib, multiple receptor tyrosine kinase inhibitor, in Japanese patients with advanced solid tumors.
Nakamichi S; Nokihara H; Yamamoto N; Yamada Y; Honda K; Tamura Y; Wakui H; Sasaki T; Yusa W; Fujino K; Tamura T
Cancer Chemother Pharmacol; 2015 Dec; 76(6):1153-61. PubMed ID: 26530955
[TBL] [Abstract][Full Text] [Related]
2. Phase I dose-escalation study and biomarker analysis of E7080 in patients with advanced solid tumors.
Yamada K; Yamamoto N; Yamada Y; Nokihara H; Fujiwara Y; Hirata T; Koizumi F; Nishio K; Koyama N; Tamura T
Clin Cancer Res; 2011 Apr; 17(8):2528-37. PubMed ID: 21372218
[TBL] [Abstract][Full Text] [Related]
3. Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma.
Hong DS; Kurzrock R; Wheler JJ; Naing A; Falchook GS; Fu S; Kim KB; Davies MA; Nguyen LM; George GC; Xu L; Shumaker R; Ren M; Mink J; Bedell C; Andresen C; Sachdev P; O'Brien JP; Nemunaitis J
Clin Cancer Res; 2015 Nov; 21(21):4801-10. PubMed ID: 26169970
[TBL] [Abstract][Full Text] [Related]
4. Pharmacodynamic change in plasma angiogenic proteins: a dose-escalation phase 1 study of the multi-kinase inhibitor lenvatinib.
Koyama N; Saito K; Nishioka Y; Yusa W; Yamamoto N; Yamada Y; Nokihara H; Koizumi F; Nishio K; Tamura T
BMC Cancer; 2014 Jul; 14():530. PubMed ID: 25047123
[TBL] [Abstract][Full Text] [Related]
5. Lenvatinib in combination with everolimus in patients with advanced or metastatic renal cell carcinoma: A phase 1 study.
Matsubara N; Naito Y; Nakano K; Fujiwara Y; Ikezawa H; Yusa W; Namiki M; Okude T; Takahashi S
Int J Urol; 2018 Nov; 25(11):922-928. PubMed ID: 30129060
[TBL] [Abstract][Full Text] [Related]
6. A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours.
Boss DS; Glen H; Beijnen JH; Keesen M; Morrison R; Tait B; Copalu W; Mazur A; Wanders J; O'Brien JP; Schellens JH; Evans TR
Br J Cancer; 2012 May; 106(10):1598-604. PubMed ID: 22516948
[TBL] [Abstract][Full Text] [Related]
7. Safety and Pharmacokinetics of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma.
Ikeda M; Okusaka T; Mitsunaga S; Ueno H; Tamai T; Suzuki T; Hayato S; Kadowaki T; Okita K; Kumada H
Clin Cancer Res; 2016 Mar; 22(6):1385-94. PubMed ID: 26500236
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and excretion of (14)C-lenvatinib in patients with advanced solid tumors or lymphomas.
Dubbelman AC; Rosing H; Nijenhuis C; Huitema AD; Mergui-Roelvink M; Gupta A; Verbel D; Thompson G; Shumaker R; Schellens JH; Beijnen JH
Invest New Drugs; 2015 Feb; 33(1):233-40. PubMed ID: 25377392
[TBL] [Abstract][Full Text] [Related]
9. Model-based treatment optimization of a novel VEGFR inhibitor.
Keizer RJ; Gupta A; Shumaker R; Beijnen JH; Schellens JH; Huitema AD
Br J Clin Pharmacol; 2012 Aug; 74(2):315-26. PubMed ID: 22295876
[TBL] [Abstract][Full Text] [Related]
10. Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma.
Ikeda K; Kudo M; Kawazoe S; Osaki Y; Ikeda M; Okusaka T; Tamai T; Suzuki T; Hisai T; Hayato S; Okita K; Kumada H
J Gastroenterol; 2017 Apr; 52(4):512-519. PubMed ID: 27704266
[TBL] [Abstract][Full Text] [Related]
11. Phase 1 study of galunisertib, a TGF-beta receptor I kinase inhibitor, in Japanese patients with advanced solid tumors.
Fujiwara Y; Nokihara H; Yamada Y; Yamamoto N; Sunami K; Utsumi H; Asou H; TakahashI O; Ogasawara K; Gueorguieva I; Tamura T
Cancer Chemother Pharmacol; 2015 Dec; 76(6):1143-52. PubMed ID: 26526984
[TBL] [Abstract][Full Text] [Related]
12. Phase I study of highly selective inhibitor of VEGFR tyrosine kinase, tivozanib, in Japanese patients with solid tumors.
Niwakawa M; Yamaguchi R; Onozawa Y; Yasui H; Taku K; Naito T; Akinaga S; Boku N; Yamamoto N
Cancer Sci; 2013 Aug; 104(8):1039-44. PubMed ID: 23679664
[TBL] [Abstract][Full Text] [Related]
13. Association of lenvatinib trough plasma concentrations with lenvatinib-induced toxicities in Japanese patients with thyroid cancer.
Nagahama M; Ozeki T; Suzuki A; Sugino K; Niioka T; Ito K; Miura M
Med Oncol; 2019 Mar; 36(5):39. PubMed ID: 30919115
[TBL] [Abstract][Full Text] [Related]
14. Effect of rifampicin on the pharmacokinetics of lenvatinib in healthy adults.
Shumaker RC; Aluri J; Fan J; Martinez G; Thompson GA; Ren M
Clin Drug Investig; 2014 Sep; 34(9):651-9. PubMed ID: 25022720
[TBL] [Abstract][Full Text] [Related]
15. Safety and tolerability of quizartinib, a FLT3 inhibitor, in advanced solid tumors: a phase 1 dose-escalation trial.
Papadopoulos KP; Ben-Ami E; Patnaik A; Trone D; Li J; Demetri GD
BMC Cancer; 2018 Aug; 18(1):790. PubMed ID: 30081867
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the effects of formulation and food on the pharmacokinetics of lenvatinib (E7080) in healthy volunteers.
Shumaker R; Aluri J; Fan J; Martinez G; Ren M; Chen K
Int J Clin Pharmacol Ther; 2014 Apr; 52(4):284-91. PubMed ID: 24548978
[TBL] [Abstract][Full Text] [Related]
17. Phase I and pharmacokinetics/pharmacodynamics study of the MEK inhibitor RO4987655 in Japanese patients with advanced solid tumors.
Nakamichi S; Nokihara H; Yamamoto N; Yamada Y; Fujiwara Y; Tamura Y; Wakui H; Honda K; Mizugaki H; Kitazono S; Tanabe Y; Asahina H; Yamazaki N; Suzuki S; Matsuoka M; Ogita Y; Tamura T
Invest New Drugs; 2015 Jun; 33(3):641-51. PubMed ID: 25809858
[TBL] [Abstract][Full Text] [Related]
18. Pharmacodynamic analysis of hypertension caused by lenvatinib using real-world postmarketing surveillance data.
Otani Y; Kasai H; Tanigawara Y
CPT Pharmacometrics Syst Pharmacol; 2021 Mar; 10(3):188-198. PubMed ID: 33471960
[TBL] [Abstract][Full Text] [Related]
19. Association of lenvatinib plasma concentration with clinical efficacy and adverse events in patients with hepatocellular carcinoma.
Hata K; Suetsugu K; Egashira N; Makihara Y; Itoh S; Yoshizumi T; Tanaka M; Kohjima M; Watanabe H; Masuda S; Ieiri I
Cancer Chemother Pharmacol; 2020 Dec; 86(6):803-813. PubMed ID: 33095285
[TBL] [Abstract][Full Text] [Related]
20. A Phase I study of safety and pharmacokinetics of fruquintinib, a novel selective inhibitor of vascular endothelial growth factor receptor-1, -2, and -3 tyrosine kinases in Chinese patients with advanced solid tumors.
Cao J; Zhang J; Peng W; Chen Z; Fan S; Su W; Li K; Li J
Cancer Chemother Pharmacol; 2016 Aug; 78(2):259-69. PubMed ID: 27299749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
